I built Entelik because I spent enough time inside mid-size pharma plants to notice the same three things. The QA Head was scared. The Plant Head was angry. And the software they were sold was built for someone else.
Most enterprise pharma software is sold on 'digital transformation' and 'AI co-pilots.' That's marketing-speak. The QA Head's actual fear is one specific document — Form 483, EIR, Warning Letter, WHO suspension — that ends a career. Entelik is built for that fear first. Everything else is downstream.
The pharma SaaS market has 30 companies racing to put AI on deviation investigations. Meanwhile the deviation isn't getting investigated because the linked equipment isn't findable because the calibration log is in a binder in the cupboard. The unsexy plumbing — calibration, planning, equipment, audit trail — is what actually moves the operational needle.
The global pharma MES vendors are priced for Pfizer. Indian formulators making ₹500cr-₹3000cr/yr can't justify it, so they stay on paper. That's not a sustainable strategy as the FDA and WHO tighten the screws. There's a gap. Entelik is built to fill it — at a price the CFO can sign without flying to Mumbai for a board approval.
Solo founder. India. Pre-revenue. Building software for an industry that's notoriously slow to change, on a price point most enterprise vendors would consider beneath them. I'm betting that the QA Head — the most cautious buyer in any plant — will switch when (a) the product handles the actual fear, (b) the price doesn't require a board meeting, and (c) the pilot terms make "no" cheap. If I'm right, this is a category. If I'm wrong, you'll get a great two-day compliance audit out of the deal.
Three retired QA Heads from large Indian formulators. Phone-able by prospects. Names will appear here as the advisory board is signed.